安心交易
不成功退款，无后顾之忧，风险服务升级。Clinical and Vaccine Immunology? (CVI) ceased publication with the December 2017 issue. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials. As of January 2018, papers in the areas of vaccine research and clinical and diagnostic immunology are published in ASM's cross-disciplinary, open access journal, mSphere?. Everything published in CVI and CDLI will continue to be available online, as noted below.mSphere’s broader audience and open access format offer an opportunity for greater impact in the field. CVI Editor in Chief Marcela Pasetti is a Senior Editor for mSphere. She will be joined by current CVI Editors Roshini Abraham, Jacqueline Achkar, Drusilla Burns, Christopher Papasian, David Pascual, Helene Rosenberg, and Patricia Wilkins, all of whom have been appointed to the mSphere Board of Editors.The Clinical and Vaccine Immunology website will remain on HighWire and all articles are freely available; full text of articles will continue to be available through PubMed Central. Permissions will continue to be obtained from CCC RightsLink via a link provided on the EC article page. mSphere searches will include CVI/ CDLI content by default.This title was published monthly, as Clinical and Diagnostic Laboratory Immunology, from 1994 to 2005 and then as Clinical and Vaccine Immunology from 2006 to 2017. In 2008 CVI became an online only journal. ISSN: 1556-679X. Previous print ISSN: 1556-6811.
临床与疫苗免疫学?(CVI)在2017年12月停刊。CVI于1994年作为临床和诊断实验室免疫学(Clinical and Diagnostic Laboratory Immunology, CDLI)首次推出，发表了一些文章，通过展示在临床、实验室和疫苗免疫学方面的发现，增进了对健康和疾病以及接种疫苗后免疫反应的理解。CVI致力于推进疫苗研究和免疫的各个方面,包括新发现的疫苗抗原和疫苗设计、开发和评估疫苗在动物模型和人类,疫苗免疫反应的特征和机制行动,控制挑战研究评估疫苗功效,疫苗研究向量,佐剂、免疫调制剂、免疫相关的保护,和临床试验。截至2018年1月，ASM的跨学科开放获取杂志mSphere?发表了疫苗研究、临床和诊断免疫学领域的论文。CVI和CDLI中发布的所有内容将继续在线提供，如下所述。mSphere更广泛的受众和开放访问格式为在该领域产生更大影响提供了机会。CVI总编辑Marcela Pasetti是mSphere的高级编辑。她将与现任CVI编辑罗希尼·亚伯拉罕、杰奎琳·阿克卡尔、德鲁西拉·伯恩斯、克里斯托弗·帕帕斯亚、大卫·帕斯夸尔、海伦·罗森伯格和帕特丽夏·威尔金斯一起加入mSphere编辑委员会。临床和疫苗免疫学网站将继续在HighWire和所有文章免费提供;文章全文将继续通过PubMed Central提供。许可将继续从CCC RightsLink通过EC文章页面提供的链接获得。默认情况下，mSphere搜索将包含CVI/ CDLI内容。1994年至2005年，《临床与诊断实验室免疫学》月刊出版，2006年至2017年，《临床与疫苗免疫学》月刊出版。2008年，CVI成为唯一的在线期刊。石头:1556 - 679 x。前一版ISSN: 1556-6811。
安心交易
不成功退款，无后顾之忧，风险服务升级。
合规备案认证机构
资质许可齐全，合规经营，用户权益有保障。
正刊保障
刊物在国家新闻出版署网可查，抵制假刊、增刊。
对公账户资金监管
交易均通过对公账户，资金安全有保障。01 选择服务并上传稿件 我们的学术顾问将根据您的需求推荐适合的服务
02 分配资深编辑和同行专家 根据您的服务方案和研究方向，为您分配资深编辑和同行专家
03 交付及反馈 每个环节的服务会在您审阅和确认后进行下一步，根据您的反馈和建议做调整
04 提升稿件质量 我们将基于您的反馈并平衡期刊的投稿要求，为您进一步优化稿件
05 提交投稿 出版专家将在您确认定稿后，为您整理并检查所有必须文件，协助您完成期刊投稿。
06 投稿跟进 及时查询稿件状态，协助您与期刊编辑沟通，根据审稿意见协助修正文章
07 拒稿支持 若期刊拒稿，您可通过拒稿咨询服务发掘稿件的改进方案，并获取365天无限次向同期刊或其他期刊的重投服务
